New treatment options for alcohol use disorder
Official title: THERAPY FOR ALCOHOL USE DISORDER
Funded at Artiam Bio INC. · NIH-10820349 · Data updated 2026-11-12
This study is looking for new ways to help people with alcohol use disorder by testing new medications that can reduce drinking without causing unwanted side effects, and if you're interested, you might have the chance to join a clinical trial to see how well these new treatments work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Artiam Bio INC. NIH-funded |
| Lab location | 1 site (Cary, United States) |
| Project start | September 25, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $368,673 |
| NIH project number | 1R41AA031392-01 |
| Project ID | NIH-10820349 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over the age of 18 who are diagnosed with alcohol use disorder.
✕Less likely to help
Patients who do not have alcohol use disorder or those who are not eligible for pharmacotherapy may not benefit from this research.
What this research studies
This research focuses on developing new therapies for alcohol use disorder (AUD), a condition affecting over 14 million adults in the US. The study aims to create second-generation cannabinoid receptor blockers that are effective in reducing alcohol consumption without causing adverse psychiatric effects, which were a concern with earlier treatments. By targeting the type 1 cannabinoid (CB1) receptor, the research seeks to maintain emotional well-being while minimizing relapse rates. Patients may participate in clinical trials to evaluate the safety and efficacy of these new compounds.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for individuals struggling with alcohol use disorder.
How similar studies have gone: Previous research has shown promise in targeting cannabinoid receptors for treating substance use disorders, but this specific approach with second-generation blockers is novel.
Where this research is happening
-
Artiam Bio INC.
Cary, United States Active
Researchers
- Principal investigator: Seltzman, Herbert H — Artiam Bio INC.
- Study coordinator: Seltzman, Herbert H
Related research
Other NIH-funded projects on the same topics.
-
Functional Connectivity-Guided TMS for Alcohol Use Disorder
A new approach uses targeted brain stimulation to help people with alcohol use disorder stay abstinent longer by focusing treatment on specific brain circuits.
-
Alcohol Use Disorder and Suicidal Behavior: Finding Why They Occur Together
A study using Swedish population data to understand why alcohol use disorder relates to suicidal thoughts and acts, with the goal of improving risk prediction and prevention.
-
Non-hallucinogenic psilocybin derivative for alcohol use disorder
A new, safer psilocybin-like compound is being studied to help people with alcohol use disorder.
-
Identifying brain proteins linked to PTSD and alcohol use disorder
Researchers are studying brain proteins that may contribute to PTSD and alcohol use disorder in US veterans to find new ways to help people who struggle with both conditions.
-
Mu and Kappa Opioid Balance in Alcohol Use Disorder
A study using brain imaging to understand how the brain’s opioid system changes during early sobriety in adults with alcohol use disorder.
-
Telehealth support to prevent suicide in people with alcohol use disorder in Tanzania
A telehealth counseling program is being adapted to help reduce suicide risk for people with alcohol use disorder in emergency departments in Tanzania.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.